Matilda Memaripour
Trainee Patent Attorney
Europe
London
Matilda joined Marks & Clerk in 2022 as a part-qualified patent attorney and is situated in the London office. Matilda has two years of prior experience with another firm before joining Marks & Clerk.
Matilda completed her undergraduate studies in Biomedical Science before graduating from Kings College London in 2020 with a First Class Master's degree in Biopharmaceuticals.
Matilda is particularly interested in immunology and the pathology of neurological diseases. Matilda honed these specialisms while completing her Master’s thesis, where she was selected to carry out a research project funded by the Michael J Fox Foundation. Her research was centred on investigating potential protein interactions between Cofilin-1 and Alpha-synuclein, which are thought to contribute to the pathology of Parkinson's disease, with the aim of identifying potential therapeutic targets.
Languages
- English
Qualifications
Postgraduate Certificate in Intellectual Property, Bournemouth University (2022)
MSc in Biopharmaceuticals, King's College London (2020)
BSc in Biomedical Science, Keele University (2018)
Search our people
Latest Insights
Unitary Patents: The First Six Months in Data
It has now been 6 months since the introduction of the Unitary Patent (UP) and the Unified Patent Court (UPC) – so how many UPs have been requested? And who is requesting them?
Read more
Double Dragona – No Goodwill When Using the Defendant’s Trademark Under License
The Federal Court of Appeal recently dismissed Dragona Carpet Supplies Mississauga Inc.'s (Dragona Mississauga) appeal of a Federal Court decision (2022 FC 1042) denying Dragona Mississauga's passing off claim.
Read more
Chiaro Technology Limited v Mayborn (UK) Limited
In the recent case of Chiaro Technology Limited v Mayborn (UK) Limited, the UK High Court confirmed that a registered design will not extend to protect aspects of shape that are required for technical function purposes even if the overall design is visually different from anything else on the market.
Read more